Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (8069)	6/9/1998 2:41:00 AM
From: John Metcalf	Respond to of 9262

{Bio chat} CYTO -- they sold the farm on the way to market. From $20+, they've become a penny stock. Sold marketing rights, manufacturing rights, etc. If they're not a bargain now, they'll be bankrupt (tossing coin). MTRA -- A possibility with FDA approval of Pyrilinks assays for bone resorption. Merck and Lilly will create some demand for assays as they market Fosamax and Evista. Haven't looked closely at Metra for awhile. BTGC -- they're in a number of niche markets. Small products, but lots of them. ELN/SHM -- used to own Elan, a big winner for me. Sheffield has a number of competitors -- DURA and INHL, to name a couple. Elan has a stellar record with acquisitions and collaborations. History would suggest that if Sheffield had arrived, Elan would buy them. Still speculative, therefore. These are not the kind of companies that I suggest as partners and targets of DD, AHP, MRK, and HOE. I'd look more at the basic research companies like ARIA, AXPH, LKST, etc., companies at the cutting edge of basic science. Not to mention HGSI, MLNM, ARQL, ABSC, MCDE, GILD, AGPH, SNAP, etc. Long list, but you'll recognize the tickers from Rick's comments.